Cervix Hypoxia FAZA

A Feasibility Study of Hypoxia Imaging in Patients With Cervix Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01549730

Enrollment

Registered

2012-03-09

Start date

2011-05-01

Completion date

2027-05-01

Last updated

2026-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervix Cancer

Brief summary

The purpose of this study is to look for low levels of oxygen (hypoxia) in your cervix cancer using a special x-ray test called a positron emission tomography (PET)scan. Hypoxia may have an effect on how cervix cancer grows and responds to treatments like radiotherapy and chemotherapy. Doctors at Princess Margaret Hospital have measured hypoxia in over 300 patients. The use of PET scans to measure hypoxia may be better and simpler than the methods used previously.

Interventions

PROCEDURE18F-Fluoroazomycin Arabinoside (18F-FAZA)

A PET scan is an imaging test that uses special radioactive dyes to measure different aspects of how your cancer acts. In this study, a dye called 18F-Fluoroazomycin Arabinoside (18F-FAZA) will be used to measure hypoxia levels in tumours. Health Canada has not approved FAZA for general use, but has approved it for use in this study.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥18 years * Histologic diagnosis of squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix * TNM (7th edition) cT1-4, N0-1, M0-1 * Intention to treat using radiotherapy with or without concurrent cisplatin chemotherapy according to the current treatment policies of the PMH Gynecology Group * No cytotoxic anti-cancer therapy for cervix cancer prior to study entry * A negative urine or serum pregnancy test within the two week interval immediately prior to PET-CT imaging, in women of child-bearing age * Ability to provide written informed consent to participate in the study

Exclusion criteria

* Prior complete or partial hysterectomy * Carcinoma of the cervical stump * Inability to lie supine for more than 30 minutes * Patients taking the drug disulfuram (Antabuse)

Design outcomes

Primary

Measure	Time frame
Number of patients treated with the PET tracer FAZA to image primary tumor hypoxia in patients with cervix cancer prior to treatment with radiotherapy and concurrent cisplatin chemotherapy	2 years

Countries

Canada

Contacts

PRINCIPAL_INVESTIGATORMichael Milosevic, MD

Princess Margaret Hospital, University Health Network

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 30, 2026